¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
10/17 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2020-10-16
Á¶È¸¼ö
296


¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ¹ÎÁö ÀÔ´Ï´Ù.


Á¦°¡ ¼±Á¤ÇÑ ³í¹®Àº 2020³âµµ nature immunology¿¡ ÃâÆÇ µÈ

"Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis" ÀÔ´Ï´Ù.

ÀÌ ³í¹®¿¡¼­´Â pneumonia·Î ÀÎÇÑ inflammation ÀÌÈÄ »óȲ¿¡¼­ alveolar macrophageÀÇ phagocytic activityÀÇ º¯È­¸¦ °üÂûÇÏ¿´

À¸¸ç alveolar macrophageÀÇ phagocytic capacity´Â ÀÌÀüÀÇ inflammatory responses¿¡ µû¶ó local tissue-derived signal¿¡ ÀÇÇØ 

Á¶ÀýÀÌ µÇ¸ç SIRPa´Â ÀÌ·¯ÇÑ »óȲ¿¡¼­ alveolar macrophageÀÇ phagocytic activity¸¦ control ÇÒ ¼ö ÀÖ´Â major regulatory role

À» ÇÒ ¼ö ÀÖ´Ù°í ¸»ÇÏ°í ÀÖ½À´Ï´Ù.  


¿­½ÉÈ÷ ÁغñÇÏ¿© Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.

°¨»çÇÕ´Ï´Ù.

¹ÎÁö ¿Ã¸²

paper link : nature.com/articles/s41590-020-0673-x
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
10/24 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä ³ª·¡ÀÔ´Ï´Ù. À̹øÁÖ ¹ßÇ¥³í¹® ¼±Á¤ÇÏ¿© ¾Ë·Áµå¸³´Ï´Ù. À̹ø¿¡ Á¦°¡ ¹ßÇ¥ÇÏ°Ô µÉ ³í¹®Àº 2019³â "Frontiers in immunology"¿¡ °ÔÀçµÈ ³í¹®À¸·Î º» ¿¬±¸ÆÀÀÌ ±âÁ¸¿¡ ¼±Ç࿬±¸·Î ¹àÇû´ø PRRSV°¨¿°½Ã Áõ°¡ÇÏ´Â IL-1 receptorantagonist(IL-1Ra)ÀÇ immunosuppressive effect¸¦ ¼¼Æ÷¼öÁØ¿¡¼­ Á» ´õ ÀÚ..
ÀÌÀü±Û
10/17 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä 10/17ÀÏ ¹ßÇ¥ÀÚ À¯ ±â¼± ÀÔ´Ï´Ù. À̹øÁÖ¿¡ Á¦°¡ ¹ßÇ¥ÇÒ ³í¹®Àº 2019³â Immunity¿¡ ÃâÆÇµÈ 'MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota' ÀÔ´Ï´Ù. ÈçÈ÷ ¾Ë·ÁÁ® ÀÖ´Â APC ¿Ü¿¡µµ intestinal epithe..